Viking Therapeutics (NASDAQ: VKTX) is a promising growth stock with a strong GLP-1 drug candidate in VK2735, which may ...

Viking Therapeutics seems to be doubling down on its hopes of making waves in the weight management market as a stand-alone ...

Analysts, who are highly bullish on the stock, have fretted for some time that Viking needed a partner to actually make the ...

In a report released today, Stephen Grambling from Morgan Stanley maintained a Buy rating on Viking Holdings Ltd (VIK – Research Report), with ...

Viking’s CEO Torstein Hagen, speaking on Viking’s fourth quarter and full year 2024 earnings conference call, highlighted ...

Viking Holdings shares dropped Tuesday as executives warned of macroeconomic "uncertainties" on the cruise operator's ...

Viking Therapeutics eyes billion-dollar obesity drug markets with pivotal trials and major production deals. Read more about ...

The website you are visiting is protected and accelerated by Imperva. Your computer may have been infected by malware and ...

Viking announced a supply deal with CordenPharma that sets it up for a standalone path to the obesity market. Read why I ...

Viking Therapeutics (NasdaqCM:VKTX) experienced a share price increase of 10% last week, coinciding with the announcement of a multi-year manufacturing agreement with CordenPharma for its V2735 ...

On today's Market Minute, Madison Mills examines the stories moving markets on Tuesday. Stellantis (STLA) shares are under ...

Viking has found a manufacturing partner ... For now, the drugs made popular by market leaders Eli Lilly & Co. (LLY) and Denmark's Novo Nordisk (NVO) (DK:NOVO.B) that treat obesity and diabetes ...